To view this email as a web page, click here

Today's Rundown

Featured Story

AstraZeneca bets $1B on Daiichi rival to Immunomedics' Trodelvy

AstraZeneca is set to pay Daiichi Sankyo $1 billion to co-develop the antibody-drug conjugate (ADC) DS-1062 outside of Japan. The deal, which features a further $5 billion in milestones, represents a big bet on a solid tumor drug that hits the same target as Immunomedics’ approved ADC Trodelvy.

read more

Top Stories

Moderna nabs a BARDA billion as its kick-starts late-stage pandemic vaccine test

Moderna has been handed an extra $472 million to run its phase 3 COVID-19 vaccine test.

read more

FDA demands more data from Solid Bio to lift gene therapy hold

The FDA has maintained a clinical hold on a phase 1/2 clinical trial of Solid Biosciences’ gene therapy treatment for Duchenne muscular dystrophy (DMD). Solid Bio will need to submit more information on subjects including the total viral load per patient to persuade the FDA to lift the clinical hold.

read more

Sponsored: FROM CHOLERA TO COVID-19: How integrated data visualizations inform decisions and impact actions

How integrated data visualizations inform decisions and impact actions. Data visualization was first used to recognize disease patterns in the 1854 London cholera outbreak. It is even more essential today.

read more

MBX Biosciences debuts with $35M to advance treatments for rare endocrine diseases

Richard DiMarchi, Ph.D., ex-Eli Lilly executive and serial entrepreneur, is getting the band back together. Along with former colleagues and a group of familiar investors, he’s setting up MBX Biosciences, a new biotech focused on rare endocrine diseases. It starts out with $34.6 million in funding from the likes of Frazier Healthcare Partners, OrbiMed and New Enterprise Associates.

read more

TCR2's T-cell therapy curbs solid tumors in early phase 1 readout

TCR2 Therapeutics' lead program shrank tumors in five patients with mesothelin-expressing cancers, with two patients seeing enough shrinkage to be considered partial responders. Of the five patients, one had ovarian cancer and four had mesothelioma, a cancer of the mesothelium, the thin tissue that lines the lung, chest wall and abdomen.

read more

FDA authorizes first COVID-19 test for screening people without symptoms

The FDA has authorized LabCorp's test for broad-based screening—including for people who have not shown any symptoms and those that do not suspect they have come into contact with someone with the disease.

read more

The top 20 drugs by global sales in 2019

For any drugmaker, taking a med to the billion-dollar sales mark—also known as a blockbuster—is a massive achievement in its own right. But for the pharmaceutical industry's bestselling drugs, some of which are blockbusters many times over, the bar is set much higher. 

read more

Resources

Whitepaper: High-Loaded Dosage Forms: Novel Platform Expands Spray-Dried Dispersion Utility

A novel spray-dried dispersion platform has been developed to faciliate high drug load applications

Whitepaper: Learn How to Navigate Pediatric Clinical Trials Under the New RACE Act

Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need.

Whitepaper How to Select the Right Data Partner to Benefit Your Business | Buyer's Guide

With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before.

eBook: Cambrex eBook - Small molecules: 2020 vision

The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet.

White Paper: Patient Switching Behaviors Impact on Adherence and Engagement: A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.”

Whitepaper: You've Decided on a Multiparticulate Dosage Form. Now What?

Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project.

Case Study: Establishing Parameters for Success

Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study.

Fact Sheet: Forecasting to Optimize Clinical Trial Supply Management

Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events